KR20210111362A - 다발성 경화증을 치료하는 방법 - Google Patents
다발성 경화증을 치료하는 방법 Download PDFInfo
- Publication number
- KR20210111362A KR20210111362A KR1020217028154A KR20217028154A KR20210111362A KR 20210111362 A KR20210111362 A KR 20210111362A KR 1020217028154 A KR1020217028154 A KR 1020217028154A KR 20217028154 A KR20217028154 A KR 20217028154A KR 20210111362 A KR20210111362 A KR 20210111362A
- Authority
- KR
- South Korea
- Prior art keywords
- fumarate
- patient
- foregoing
- formula
- certain embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Business, Economics & Management (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Theoretical Computer Science (AREA)
- Entrepreneurship & Innovation (AREA)
- Educational Administration (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020247007355A KR20240035912A (ko) | 2014-11-17 | 2015-11-16 | 다발성 경화증을 치료하는 방법 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080783P | 2014-11-17 | 2014-11-17 | |
| US62/080,783 | 2014-11-17 | ||
| US201562140255P | 2015-03-30 | 2015-03-30 | |
| US62/140,255 | 2015-03-30 | ||
| US201562232963P | 2015-09-25 | 2015-09-25 | |
| US62/232,963 | 2015-09-25 | ||
| KR1020177016298A KR102299842B1 (ko) | 2014-11-17 | 2015-11-16 | 다발성 경화증을 치료하는 방법 |
| PCT/US2015/060850 WO2016081355A1 (en) | 2014-11-17 | 2015-11-16 | Methods of treating multiple sclerosis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177016298A Division KR102299842B1 (ko) | 2014-11-17 | 2015-11-16 | 다발성 경화증을 치료하는 방법 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247007355A Division KR20240035912A (ko) | 2014-11-17 | 2015-11-16 | 다발성 경화증을 치료하는 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210111362A true KR20210111362A (ko) | 2021-09-10 |
Family
ID=54771192
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217028154A Ceased KR20210111362A (ko) | 2014-11-17 | 2015-11-16 | 다발성 경화증을 치료하는 방법 |
| KR1020177016298A Expired - Fee Related KR102299842B1 (ko) | 2014-11-17 | 2015-11-16 | 다발성 경화증을 치료하는 방법 |
| KR1020247007355A Ceased KR20240035912A (ko) | 2014-11-17 | 2015-11-16 | 다발성 경화증을 치료하는 방법 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177016298A Expired - Fee Related KR102299842B1 (ko) | 2014-11-17 | 2015-11-16 | 다발성 경화증을 치료하는 방법 |
| KR1020247007355A Ceased KR20240035912A (ko) | 2014-11-17 | 2015-11-16 | 다발성 경화증을 치료하는 방법 |
Country Status (13)
| Country | Link |
|---|---|
| US (9) | US20170354630A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3804711A1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6786486B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20210111362A (cg-RX-API-DMAC7.html) |
| CN (6) | CN113368092A (cg-RX-API-DMAC7.html) |
| AU (5) | AU2015350213A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2967619C (cg-RX-API-DMAC7.html) |
| EA (1) | EA038370B1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL269885B (cg-RX-API-DMAC7.html) |
| MA (2) | MA40985A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017006473A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016081355A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201703207B (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10391160B2 (en) | 2014-03-14 | 2019-08-27 | Biogen Ma Inc. | Dimethyl fumarate and vaccination regimens |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| IL252962B (en) | 2015-02-08 | 2022-07-01 | Alkermes Pharma Ireland Ltd | Monomethylfumarate prodrug compositions |
| AU2017240747B2 (en) | 2016-04-01 | 2021-10-21 | Sionic Energy, Inc. | Modified ionic liquids containing phosphorus |
| WO2019018432A1 (en) | 2017-07-17 | 2019-01-24 | NOHMs Technologies, Inc. | ELECTROLYTES CONTAINING PHOSPHORUS |
| EP4578850A3 (en) * | 2019-04-17 | 2025-10-15 | Myto Therapeutics, Inc. | Prodrugs of monomethyl fumarate |
| PH12021552668A1 (en) * | 2019-05-31 | 2022-09-19 | Curacle Co Ltd | Enteric tablet containing dimethyl fumarate |
| TW202116297A (zh) * | 2019-07-03 | 2021-05-01 | 西班牙商布爾奴爾法碼有限公司 | 組合療法之方法、組成物與套組 |
| TW202131914A (zh) | 2019-10-30 | 2021-09-01 | 西班牙商布爾奴爾法碼有限公司 | 用於神經疾病或病狀的治療之新治療方案 |
| CN111440771A (zh) * | 2020-03-17 | 2020-07-24 | 中山大学附属第三医院 | 一种含有clcn2纯合突变的白质脑病患者特异诱导多能干细胞系 |
| WO2021144478A2 (en) | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
| KR102713565B1 (ko) * | 2020-11-27 | 2024-10-07 | 주식회사 뷰노 | 의료 영상 기반의 뇌백질 병변 탐지 방법 |
| WO2022203432A1 (ko) * | 2021-03-25 | 2022-09-29 | 주식회사 큐라클 | 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물 |
| KR102566549B1 (ko) * | 2021-06-08 | 2023-08-14 | 제이투에이치바이오텍 (주) | 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도 |
| US20250181224A1 (en) * | 2023-12-01 | 2025-06-05 | Lemon Inc. | Implementing dialog-based image editing |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| SI1799196T1 (sl) | 2004-10-08 | 2016-10-28 | Forward Pharma A/S | Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline |
| HUE047230T2 (hu) | 2006-02-28 | 2020-04-28 | Biogen Ma Inc | Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei |
| HUE032251T2 (en) * | 2007-02-08 | 2017-09-28 | Biogen Ma Inc | Neuroprotection in demyelinating diseases |
| MX2011001341A (es) | 2008-08-19 | 2011-03-29 | Xenoport Inc | Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso. |
| BR112012017014B1 (pt) | 2010-01-11 | 2021-07-20 | Biogen Ma Inc | Métodos para detecção de anticorpos de vírus jc |
| MX2013013781A (es) * | 2011-05-26 | 2014-01-08 | Biogen Idec Inc | Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina. |
| HUE061244T2 (hu) | 2011-05-31 | 2023-06-28 | Biogen Ma Inc | A PML kockázat értékelésének módszere |
| CA2862885C (en) | 2012-02-07 | 2020-06-02 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
| US20140057918A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
| WO2014071371A1 (en) | 2012-11-05 | 2014-05-08 | Xenoport, Inc. | Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate |
| AR094277A1 (es) | 2012-12-21 | 2015-07-22 | Biogen Idec Inc | Derivados de fumarato sustituidos con deuterio |
| EP3243511B1 (en) | 2012-12-21 | 2019-03-20 | ratiopharm GmbH | Prodrugs of monomethylfumarate (mmf) |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US20140322251A1 (en) | 2013-04-26 | 2014-10-30 | Michael Ruff | Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions |
| CA2919381A1 (en) | 2013-08-01 | 2015-02-05 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| CA2939990C (en) | 2014-02-28 | 2018-07-10 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US10391160B2 (en) | 2014-03-14 | 2019-08-27 | Biogen Ma Inc. | Dimethyl fumarate and vaccination regimens |
| CA2962916C (en) | 2014-10-08 | 2021-06-15 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| WO2017040272A1 (en) | 2015-08-31 | 2017-03-09 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| WO2017151184A1 (en) | 2016-02-29 | 2017-09-08 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10523918B2 (en) | 2017-03-24 | 2019-12-31 | Samsung Electronics Co., Ltd. | System and method for depth map |
-
2015
- 2015-11-15 MA MA040985A patent/MA40985A/fr unknown
- 2015-11-16 EP EP20195649.7A patent/EP3804711A1/en not_active Withdrawn
- 2015-11-16 CN CN202110623848.XA patent/CN113368092A/zh active Pending
- 2015-11-16 CN CN202110623846.0A patent/CN113368091A/zh active Pending
- 2015-11-16 KR KR1020217028154A patent/KR20210111362A/ko not_active Ceased
- 2015-11-16 WO PCT/US2015/060850 patent/WO2016081355A1/en not_active Ceased
- 2015-11-16 US US15/527,252 patent/US20170354630A1/en not_active Abandoned
- 2015-11-16 MX MX2017006473A patent/MX2017006473A/es unknown
- 2015-11-16 IL IL269885A patent/IL269885B/en unknown
- 2015-11-16 CN CN202211204481.9A patent/CN115531366A/zh active Pending
- 2015-11-16 EP EP22214115.2A patent/EP4215191A1/en active Pending
- 2015-11-16 CA CA2967619A patent/CA2967619C/en active Active
- 2015-11-16 CN CN201580072773.3A patent/CN107106530A/zh active Pending
- 2015-11-16 KR KR1020177016298A patent/KR102299842B1/ko not_active Expired - Fee Related
- 2015-11-16 EP EP15804260.6A patent/EP3220907A1/en not_active Ceased
- 2015-11-16 KR KR1020247007355A patent/KR20240035912A/ko not_active Ceased
- 2015-11-16 CN CN202110624861.7A patent/CN113368093A/zh active Pending
- 2015-11-16 JP JP2017526549A patent/JP6786486B2/ja active Active
- 2015-11-16 CN CN202211204459.4A patent/CN115501218A/zh active Pending
- 2015-11-16 MA MA053882A patent/MA53882A/fr unknown
- 2015-11-16 AU AU2015350213A patent/AU2015350213A1/en not_active Abandoned
- 2015-11-16 EA EA201791101A patent/EA038370B1/ru unknown
-
2017
- 2017-05-09 ZA ZA2017/03207A patent/ZA201703207B/en unknown
- 2017-05-15 IL IL252296A patent/IL252296B/en unknown
- 2017-07-11 US US15/647,036 patent/US20180000770A1/en not_active Abandoned
- 2017-07-11 US US15/647,016 patent/US11129806B2/en active Active
-
2018
- 2018-07-24 US US16/043,641 patent/US20190008817A1/en not_active Abandoned
- 2018-10-29 US US16/173,723 patent/US10959972B2/en active Active
- 2018-11-27 JP JP2018221109A patent/JP6830941B2/ja active Active
-
2020
- 2020-07-22 US US16/936,398 patent/US11007166B2/en active Active
- 2020-09-08 JP JP2020150484A patent/JP2020196760A/ja not_active Withdrawn
- 2020-09-24 AU AU2020239734A patent/AU2020239734A1/en not_active Abandoned
- 2020-10-15 US US17/071,740 patent/US11007167B2/en active Active
-
2021
- 2021-05-17 US US17/321,788 patent/US11246850B2/en active Active
- 2021-11-15 AU AU2021269298A patent/AU2021269298A1/en not_active Abandoned
-
2022
- 2022-09-13 JP JP2022145173A patent/JP2022168243A/ja not_active Withdrawn
-
2024
- 2024-05-23 AU AU2024203437A patent/AU2024203437A1/en not_active Abandoned
-
2025
- 2025-02-07 US US19/048,181 patent/US20260007627A1/en active Pending
- 2025-05-12 JP JP2025079812A patent/JP2025109834A/ja active Pending
-
2026
- 2026-06-10 AU AU2026204454A patent/AU2026204454A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102299842B1 (ko) | 다발성 경화증을 치료하는 방법 | |
| US20080044382A1 (en) | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds | |
| CN119212708A (zh) | 用于髓鞘少突胶质细胞糖蛋白抗体疾病(mogad)的治疗性酪氨酸激酶抑制剂 | |
| EP3250198A1 (en) | Multiple sclerosis treatment regimen using dimethyl fumarate | |
| HK40097430A (en) | Composition comprising a fumarate for use in a method of treating multiple sclerosis | |
| HK40047494A (en) | Methods of treating multiple sclerosis | |
| NZ731528B2 (en) | Methods of treating multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| PX0601 | Decision of rejection after re-examination |
St.27 status event code: N-2-6-B10-B17-rex-PX0601 |
|
| X601 | Decision of rejection after re-examination | ||
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |